PRODUCT OVERVIEW & COMPOSITION
Brand / Manufacturer: Bioniche Pharma
Active Ingredient: Trenbolone Acetate (100 mg/ml)
Pharmacological Class: Synthetic $19\text{-Nortestosterone}$ Derivative / Short-Ester Anabolic-Androgenic Steroid
This single-entity injectable formulation by Bioniche Pharma contains Trenbolone Acetate at a concentration of 100 mg/ml. Known for its strong binding affinity to androgen receptors, Trenbolone Acetate is a potent short-esterified $19\text{-nor}$ compound engineered by Bioniche Pharma to deliver rapid, high-potency anabolic activity without aromatizing into estrogen, driving significant lean tissue preservation, nitrogen retention, and cellular recovery.
CLINICAL PHARMACOLOGY & MECHANISM OF ACTION
Trenbolone Acetate exerts powerful anabolic and androgenic actions through high-affinity binding to intracellular androgen receptors. It significantly enhances protein synthesis, accelerates cellular nitrogen uptake, and increases insulin-like growth factor 1 (IGF-1) production within skeletal muscle tissue. Because the molecule lacks a $4,5$-double bond aromatization site, it does not convert to estradiol. The attached acetate ester provides a rapid pharmacokinetic release, necessitating frequent administration to sustain consistent serum concentrations.
INDICATIONS & CLINICAL USE
- Anabolic therapy for promoting severe protein anabolism, cellular regeneration, and tissue preservation.
- Adjunctive management of severe catabolic states, muscle wasting disorders, and involuntary weight loss under clinical supervision.
CONTRAINDICATIONS
- Male patients with known or suspected carcinoma of the prostate gland or male breast cancer.
- Female patients who are pregnant, may become pregnant, or are nursing, due to severe risks of fetal virilization, malformation, and endocrine disruption.
- Pediatric patients, adolescents, and children.
- Patients with documented hypersensitivity or allergic reaction to Trenbolone Acetate, carrier oils, or inactive components in Bioniche Pharma formulations.
WARNINGS & SPECIAL PRECAUTIONS
- Cardiovascular Supervision: Middle-aged and elderly male patients presenting with angina pectoris, prior coronary artery disease, or severe circulatory disorders must receive Trenbolone treatment only under strict medical supervision.
- Nephrotoxicity & Renal Monitoring: Prolonged administration or high dosages may exert strain on the kidneys and lead to renal discomfort. Dark-colored urine serves as an early clinical indicator of potential renal burden; fluid intake and renal function tests should be actively monitored.
ADVERSE REACTIONS
- Cardiovascular & Systemic: Marked elevation in blood pressure (hypertension), nasal bleeding (epistaxis), hot flashes, headaches, and nausea.
- Dermatological & Behavioral: Severe oily skin, acne vulgaris, and noticeable increases in aggressiveness, irritability, or mood alterations.
- Endocrine & Reproductive: Deep suppression of the endogenous Hypothalamic-Pituitary-Testicular Axis (HPTA), leading to testicular atrophy, oligospermia, and secondary hypogonadism.
DOSAGE & ADMINISTRATION
Bioniche Pharma Trenbolone Acetate is formulated strictly for deep intramuscular injection. Due to the fast-acting nature of the acetate ester, administration must be frequent and dosage adjusted based on individual patient response and clinical oversight:
- Adult Dosage: The standard dosage ranges from 100 mg administered 1 to 3 times per week (100 mg to 300 mg total weekly dose).
- Restricted Populations: Strictly contraindicated for use in children or female patients.
STORAGE & HANDLING
Store Bioniche Pharma injectable products in a cool, dry place protected from direct light exposure and excess heat. Do not refrigerate or freeze. Keep strictly out of reach and sight of children.